Coorparoo

Researchers are studying weight reduction in adults living with obesity or overweight who also have type 2 diabetes. The study evaluates two drugs, macupatide and eloralintide, given alone or together, to understand their effects on body weight. This Phase 2 trial is designed to assess these treatments in a controlled setting with participants randomly assigned to different groups. Participants will receive one of four treatments macupatide with an eloralintide placebo, eloralintide with a macupatide placebo, both macupatide and eloralintide together, or double placebo. All drugs are administered by subcutaneous injection. The main treatment period lasts about 32 weeks, during which the effects on body weight and diabetes-related measures are monitored. Throughout the study, participants will have evaluations including body weight, hemoglobin A1c levels, body mass index, and fasting glucose at the start and at week 32. The study involves a total participation duration of about 48 weeks, allowing for treatment, follow-up, and monitoring. The sponsor is Eli Lilly and Company, and the trial uses double-blind, randomized design to compare treatments fairly.

This research aims to evaluate how tirzepatide affects body weight and cardiovascular risk factors in adolescents aged 12 to 17 who have obesity along with multiple weight-related health conditions. The study is a Phase 3 clinical trial focusing on the safety and effectiveness of tirzepatide combined with healthy nutrition and physical activity. Participants will be randomly assigned to receive either tirzepatide or a placebo through weekly injections under the skin. The main study period lasts about 72 weeks with up to 23 visits, and participants who completed a prior related study and meet certain criteria may continue receiving tirzepatide for an additional 156 weeks while maintaining lifestyle interventions. During the study, participants will undergo various assessments including measurements of body mass index BMI, blood pressure, blood sugar HbA1c, triglycerides, body fat by DXA scan, and sleep apnea index. Researchers will monitor changes from baseline to week 72 in these areas to evaluate the treatments impact. Safety and adherence to the study schedule will also be closely observed throughout the trial.

Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss mainly on the head and face but possibly on other body parts. This research evaluates the safety, effectiveness, and tolerance of upadacitinib, an approved drug, in adolescents and adults with severe AA. The study is a Phase 3 randomized, placebo-controlled, double-blind trial enrolling about 1500 participants worldwide. Participants are randomly assigned to one of three groups receiving different treatments two doses of upadacitinib or placebo. In initial periods, some may switch from placebo to upadacitinib based on their Severity of Alopecia Tool SALT score. Those completing early parts may enter an extension phase receiving upadacitinib for up to 108 weeks. Treatment involves taking oral tablets once daily for up to 160 weeks, with possible re-randomization at Weeks 24 and 52. Throughout the study, participants attend regular clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires to track treatment effects. Researchers measure hair loss improvement using SALT scores and record adverse events over approximately 164 weeks. Participants are followed for up to 30 days after their last dose for safety monitoring.

Researchers are evaluating the safety and efficacy of FB102, an intravenous drug, in patients with non-segmental vitiligo. This randomized, double-blind, placebo-controlled, multi-center Phase 1 study aims to better understand how FB102 may affect skin pigmentation in adults aged 18 to 75 years who have this condition. Approximately 64 participants will take part in the trial sponsored by Forte Biosciences, Inc. Participants will be randomly assigned to receive either FB102 or a matching placebo, both given through intravenous infusion. The treatment period lasts up to 16 weeks after the first dose administration. During this time, the study will closely monitor participants receiving these treatments to compare their effects on vitiligo. Participants will undergo regular assessments including facial and total vitiligo area scoring indexes to measure changes in skin pigmentation. Safety will also be evaluated by tracking treatment-emergent and serious adverse events. The study includes scheduled visits and evaluations up to 16 weeks post-treatment. This allows researchers to gather detailed information on the drugs impact and participant safety throughout the study period.

Researchers are evaluating the safety and effectiveness of FB102 in adults with severe to very severe alopecia areata, a condition causing significant hair loss. This randomized, double-blind, placebo-controlled Phase 1 study aims to better understand how FB102 works compared to a placebo in this patient group. Up to 32 participants will be randomly assigned in a 3 to 1 ratio to receive either FB102 or a matching placebo. Both treatments are given intravenously. The study will monitor participants over several weeks, assessing safety and changes in hair loss severity. Participants will be involved in the study for up to 36 weeks after their first dose. During this time, they will undergo regular evaluations including tracking treatment-related side effects and measuring changes in hair loss using the Severity of Alopecia Tool SALT score. Researchers will carefully monitor safety and treatment responses throughout the study.

Researchers are evaluating the safety, pharmacokinetics, and pharmacodynamics of TRB-061, a drug given by subcutaneous injection, in healthy adults and patients with moderate-to-severe atopic dermatitis AD. This Phase 1a1b randomized, double-blind, placebo-controlled study includes healthy participants and those with AD to better understand how TRB-061 behaves in the body and its effects. The study is divided into three parts to assess single and multiple doses in different groups. In Part 1, healthy participants receive a single ascending dose of TRB-061 or placebo and are followed for 12 weeks. Part 2 involves healthy participants receiving three doses of TRB-061 or placebo every four weeks over eight weeks, followed by a 10-week follow-up. Part 3 includes patients with moderate-to-severe AD randomized to receive either one of two doses of TRB-061 or placebo every four weeks for 12 weeks. Participants in Part 3 may opt into a crossover period where treatment assignments are switched for another 12 weeks, followed by a final follow-up until the end of the study. Participants will undergo safety assessments including monitoring of adverse events, pharmacokinetic blood tests, and clinical evaluations throughout the study and follow-up periods. Healthy participants are screened for general health and ECG abnormalities before enrollment, while AD patients must have a confirmed diagnosis and moderate-to-severe disease. Regular visits are scheduled for dosing and evaluations, and researchers will measure safety outcomes primarily by tracking adverse events from screening through follow-up. The study aims to complete by February 2028.

Researchers are evaluating whether increasing the use of finger-stick point-of-care testing for hepatitis C virus HCV infection improves diagnosis and treatment rates. The study focuses on people at risk for HCV infection, recruited from various settings such as drug treatment clinics, needle and syringe programs, homelessness services, mental health services, prisons, and mobile outreach. This observational cohort study aims to address challenges in HCV elimination caused by reduced treatment uptake and barriers in current diagnostic pathways. Participants will attend a single visit to receive point-of-care HCV testing using finger-stick methods. Testing includes rapid HCV antibody tests, and if positive, further HCV RNA testing is performed to detect active infection. Those with detectable HCV RNA will be linked to standard care for further assessment and treatment outside the study. Participants will complete a self-administered survey during the visit. No treatment is provided as part of this study. During the study, researchers will measure how many participants with active HCV infection start treatment within 12 weeks after testing. They will also evaluate acceptance of testing, prevalence of active infection, treatment initiation timing, treatment completion, and virus clearance rates up to 52 weeks following testing. Data from surveys will be linked to administrative records to assess long-term health outcomes. Participation involves only one study visit for testing and survey completion.

Researchers are evaluating the use of finger-stick point-of-care testing for hepatitis C virus HCV infection in people at risk of acquiring HCV. The study aims to see if scaling up this testing approach increases diagnosis and treatment rates. The research addresses challenges in current testing pathways that require multiple visits, which reduce the number of people who receive a diagnosis and treatment. It is an observational study led by the Kirby Institute, focusing on improving HCV elimination efforts in Australia by 2030. Participants will be recruited from various settings serving people at risk, such as drug treatment clinics, needle and syringe programs, homelessness services, mental health services, prisons, and mobile outreach. Clinic staff will offer point-of-care HCV RNA testing using finger-stick samples during routine service access. There is no treatment provided as part of this study, but participants who test positive for HCV RNA will be connected to standard care for further evaluation and treatment. Throughout the study, participants who undergo point-of-care testing will be included in data collection. Researchers will monitor the proportion of HCV-infected participants who start treatment within 12 weeks of enrollment, the acceptance rate of testing, prevalence of infection, timing and completion of treatment, and viral response over a year. The study involves ongoing observation linked to routine care, with no intervention beyond testing. Total participation duration varies as the study is observational and ongoing.